Overview

A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults

Status:
COMPLETED
Trial end date:
2024-07-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK), drug-drug interaction, and safety and tolerability of VX-993 in healthy participants.
Phase:
PHASE1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Gemfibrozil
Itraconazole
Midazolam